TheraRadar
← Back
Data updated: Jun 28, 2026

HOPE PHARMS

Pharma
Pharmaceuticals Execution: Needs Improvement

HOPE PHARMS is a pharmaceutical company with 3 FDA-approved products.

2011
Since
3
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

HOPE PHARMS's Key Drugs

HOPE PHARMS's core commercial portfolio centers on NITHIODOTE — its most strategically important drugs approved in the last 15 years.

NITHIODOTE
Other

Cyanide Poisoning

Cytochrome a3 Approved 2011

HOPE PHARMS's Recent FDA Approvals

New NDA/BLA approvals for HOPE PHARMS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

HOPE PHARMS's Therapeutic Areas

Disease areas where HOPE PHARMS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

HOPE PHARMS Pipeline Snapshot

Active clinical trials for HOPE PHARMS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • NITHIODOTE leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Active trial monitoring
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 0/0 completed
  • • Speed: N/A months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges